UNSPSC 51141523: Paramethadione

This classification denotes an anticonvulsant agent with the molecular formula C7H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z615FRW64N, chemically known as 3,5-dimethyl-5-ethyloxazolidine-2,4-dione but generally known as paramethadione, which bears US NIH Compound Identifier 8280. European Medicines Agency schedules Paramethadione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09613MIG. The term PARAMETHADIONE is an International Non-Proprietary Name.

UNSPSC 51141523 Paramethadione is a Commodity code that nominally designates a specific anticonvulsant pharmaceutical product, but recent state and local procurement activity under this code does not reflect purchases of paramethadione itself. Instead, the code appears to have been applied to broader pharmaceutical procurement efforts spanning naloxone, multi-source generic pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The actual buying patterns show state and local health agencies, cooperative purchasing alliances, and county health departments procuring finished pharmaceutical products, including emergency medications and generic drug inventories distributed through established pharmaceutical wholesalers and direct-to-manufacturer channels. Work centers on establishing supply agreements for medications and related health products to support public health initiatives, community health programs, and state employee benefit plans.

Activity appears concentrated among state health and human services departments and county health systems, with cooperative purchasing vehicles playing a significant role in multi-jurisdictional procurement. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription capabilities; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) under the Minnesota Department of Administration's Office of State Procurement posted an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, to establish multi-state contracts for generic pharmaceuticals and OTC products through three authorized wholesalers with awards effective July 1, 2026; and Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. Recent opportunities involve Texas, Minnesota, Florida, and Oregon through cooperative purchasing participation. The code shows little evidence of paramethadione-specific procurement and may warrant review for taxonomy alignment with actual pharmaceutical supply activity.